BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play

2026-07-12 09:55:00 ET

The last time I spoke about BridgeBio Pharma ( BBIO ) it was with a Seeking Alpha article entitled " BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum ." With respect to this article, I mentioned that the FDA had accepted the submission of acoramidis for review for the treatment of patients with transthyretin amyloid cardiomyopathy [ATTR-CM]. I had rated this stock a "Strong Buy" rating at that time, and today I'm going to maintain this rating. There are actually several reasons why I believe this should be the case even though the stock has traded higher by 245.08% since I last wrote about it. First and foremost, the company did indeed end up receiving U.S. marketing approval of Attruby [acoramidis] for the treatment of patients with ATTR-CM....

Read the full article on Seeking Alpha

For further details see: